MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

407

Employees407

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

407

Employees407

MNKD Key Statistics

Market cap

1.39B

Market cap1.39B

Price-Earnings ratio

47.34

Price-Earnings ratio47.34

Dividend yield

—

Dividend yield—

Average volume

1.80M

Average volume1.80M

High today

$4.77

High today$4.77

Low today

$4.56

Low today$4.56

Open price

$4.74

Open price$4.74

Volume

1.28M

Volume1.28M

52 Week high

$7.63

52 Week high$7.63

52 Week low

$4.34

52 Week low$4.34

MNKD News

TipRanks 3d

MannKind’s Strong Financial Performance and Promising Pipeline Drive Buy Rating

Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on MannKind (MNKD – Research Report). The associated price target remains the same...

Simply Wall St 4d

Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that MannKind Corporation ( ) filed its first-quarter result this time last week. The early response was not positive, with shar...

TipRanks 6d

MannKind Corporation’s Earnings Call: Optimistic Outlook Amid Challenges

MannKind Corporation ((MNKD)) has held its Q1 earnings call. Read on for the main highlights of the call. MannKind Corporation’s recent earnings call conveyed...

Analyst ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

More MNKD News

TipRanks 6d

MannKind’s Promising Growth Potential: Buy Rating Backed by Strong Financials and Strategic Advancements

MannKind (MNKD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush reiterated a Buy...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Palantir Technologies